Experience

Femasys Inc.

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Director

  • 2022 - Present

  Atlanta, Georgia, United States Women founded and led biomedical company with an unwavering commitment to develop novel solutions for women worldwide. First-of-its-kind solutions for infertility and permanent birth control addressing multi-billion dollar market opportunities.



USM Maryland Momentum Fund - Venture Capital

• Member Of The Board Of Advisors

  • Aug 2020 - Present

  Baltimore, Maryland, United States



Princeton Capital Advisors

• United States
• Business Consulting and Services
• 1 - 100 Employee

• Senior Advisor

  • 2020 - Present

  Baltimore, Maryland Princeton Capital Advisors is a global independent advisory firm that provides innovative, unconflicted and fact-based strategic advice to a diverse client base on many of their most important financial, investment and transactional decisions.



AsclepiX Therapeutics, Inc.

• Chief Executive Officer and Board Member

  • Jul 2016 - Feb 2020

  Baltimore, Maryland, United States AsclepiX Therapeutics is focused on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world with the freedom to live their best lives. Chief Executive Officer and Board Member • Raised $21 Million via non-dilutive and private investor funding and brought in the Venture Capital firm Xontogeny / Perceptive for the $35M Series A investment. Negotiated exclusive… Show more AsclepiX Therapeutics is focused on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world with the freedom to live their best lives. Chief Executive Officer and Board Member • Raised $21 Million via non-dilutive and private investor funding and brought in the Venture Capital firm Xontogeny / Perceptive for the $35M Series A investment. Negotiated exclusive license from Johns Hopkins University for the development of novel therapeutics in ophthalmology and oncology. Created and led successful development of AXT107 ophthalmology programs in collaboration with FDA for novel toxicology program and animal models. • Spearheaded innovative formulation of new products in-house and global GMP manufacturing of AXT107. Championed small high-performing team to progress three novel products from concept to pre-clinical studies. Show less



Alba Therapeutics, Inc.

• Chief Executive Officer

  • 2008 - 2016

  Baltimore, MD Alba Therapeutics, Inc. Baltimore, MD Start-up clinical-stage Biotechnology Company developing novel therapeutics for autoimmune and gastrointestinal diseases. Chief Executive Officer • Recruited to lead business development, manage pharmaceutical alliances, create marketing and branding strategies for clinical trials. Closed Licensing Deal for Phase III Asset • Raised and managed funding from VC investors and pharmaceutical partnerships. Negotiated term sheets for licensing… Show more Alba Therapeutics, Inc. Baltimore, MD Start-up clinical-stage Biotechnology Company developing novel therapeutics for autoimmune and gastrointestinal diseases. Chief Executive Officer • Recruited to lead business development, manage pharmaceutical alliances, create marketing and branding strategies for clinical trials. Closed Licensing Deal for Phase III Asset • Raised and managed funding from VC investors and pharmaceutical partnerships. Negotiated term sheets for licensing and option agreements. Closed deal with Innovate Biopharmaceuticals, Inc. now 9 Meters Biopharma. • Promoted to CEO in 2011, raised $31 Million up-front to fund Phase 2b clinical trial, spearheaded GMP manufacturing, development of CeD PRO for primary endpoint. Trial was over-enrolled with 342 patients with celiac disease, randomization was complete two months early, and trial was $1 Million under budget. Show less



Sigma-Tau Pharmaceuticals

• Vice President Marketing and Sales

  • 2004 - 2007

  Gaithersburg, Maryland Sigma-Tau Pharmaceuticals, Inc. Gaithersburg, MD Clinical-stage Biotechnology Company developing novel therapeutics for Orphan and Rare Diseases. VP Business Development, Marketing & Sales • Transitioned company to new Orphan drug and rare disease corporate strategy and structure. Established solid procedures, novel corporate branding, recruited the U.S. oncology sales team. • Spearheaded business development and identified and in-licensed three late stage products Cystaran®… Show more Sigma-Tau Pharmaceuticals, Inc. Gaithersburg, MD Clinical-stage Biotechnology Company developing novel therapeutics for Orphan and Rare Diseases. VP Business Development, Marketing & Sales • Transitioned company to new Orphan drug and rare disease corporate strategy and structure. Established solid procedures, novel corporate branding, recruited the U.S. oncology sales team. • Spearheaded business development and identified and in-licensed three late stage products Cystaran®, Defitelio®, and Eurartesim® and created their global strategy and pre-marketing campaigns. • Drove estimated market value by 515%, from $122 Million to $750 Million in 3 years. Created marketing and sales plans for approved products in oncology, biologics, rare diseases, and kidney disease. Show less



Merck

• Global Marketing Associate Director (Multiple roles)

  • 1989 - 2003

  Merck & Co., Inc. Whitehouse Station, NJ Global Marketing Associate Director (Multiple roles) • Led launch and managed global marketing for 1st ARB Cozaar® & Hyzaar® and doubled sales in 2 years to $3.1 Billion annual revenue. Spearheaded 2 new indication launches with RENAAL for renal protection and LIIFE for prevention of stroke. • Drove sales 51% to $769 Million in 2000 and accountable for U.S. marketing for Cozaar® and Hyzaar®. Managed market research, regulatory, research… Show more Merck & Co., Inc. Whitehouse Station, NJ Global Marketing Associate Director (Multiple roles) • Led launch and managed global marketing for 1st ARB Cozaar® & Hyzaar® and doubled sales in 2 years to $3.1 Billion annual revenue. Spearheaded 2 new indication launches with RENAAL for renal protection and LIIFE for prevention of stroke. • Drove sales 51% to $769 Million in 2000 and accountable for U.S. marketing for Cozaar® and Hyzaar®. Managed market research, regulatory, research, manufacturing, public affairs, investor relations, and KOL advocate development. Spearheaded clinical trial, label change with FDA and coordinated the launch of the African American Initiative with inspiration from former Surgeon General David Satcher, MD, PhD. • Led U.S. launch for Cozaar® and Hyzaar®, generating $507 Million in sales in 1998. Coordinated core marketing promotion of product line and managed a promotional budget of $96M. Successfully led partnership with Merck and DuPont. • Directed global launch of chickenpox vaccine Varivax®, led DTC campaign, obtained $500M in sales post launch, began Phase III clinical work on Zostavax® for shingles. Led the global marketing team for Varivax®, M-M-R® II, Recombivax HB®, PedvaxHIB®, Pneumovax®23, and Comvax® for U.S., EU, Japan, China, Asia, and Latin America. • Directed U.S. launch of Zocor® marketing programs, including “Targeted Resource Blitz-Zocor” with a $56,000 budget, increasing sales by $10 Million in five months post launch, leading to $5.6 Billion yearly revenue. Managed KOLs and the $4.6 Million HEL budget. Show less